ARTICLE | Clinical News
Adcirca tadalafil: Phase III data
June 22, 2009 7:00 AM UTC
Data from the double-blind, international Phase III PHIRST-1 trial in 405 patients showed that once-daily 40 mg Adcirca tadalafil met the primary endpoint of a significant increase in 6MWD vs. placebo...